Protecting the pump: Controlling myocardial inflammatory responses

Annual Review of Physiology

Volumn 68, Issue , 2006, Pages 67-95

  Taqueti, Viviany R ^a   Mitchell, Richard N ^a   Lichtman, Andrew H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adaptive immunity; Heart; Inflammation; Innate immunity; Myocarditis

Indexed keywords

CYTOKINE; GAMMA INTERFERON;

ANTIINFLAMMATORY ACTIVITY; FEEDBACK SYSTEM; HEART FUNCTION; HEART INJURY; HUMAN; IMMUNE RESPONSE; IMMUNITY; ISCHEMIA; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ANIMALS; CYTOKINES; GRAFT REJECTION; HEART; HEART TRANSPLANTATION; HUMANS; INFLAMMATION; MYOCARDIAL REPERFUSION INJURY; MYOCARDITIS; MYOCARDIUM; NEUTROPHILS; T-LYMPHOCYTES;

EID: 33645999101     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.68.040104.124611     Document Type: Review

References (160)

1. Ludwig L, Schertel E, Pratt J, McClure D, Ying A, et al. 1997. Impairment of left ventricular function by acute cardiac lymphatic obstruction. Cardiovasc. Res. 33:164-71
2. Geissler H, Bloch W, Forster S, Mehlhorn U, Krahwinkel A, et al. 2003. Morphology and density of initial lymphatics in human myocardium determined by immunohistochemistry. Thorac. Cardiovasc. Surg. 51:244-48
3. Bonaventura J, Gow A. 2004. NO and superoxide: opposite ends of the seesaw in cardiac contractility. Proc. Natl. Acad. Sci. USA 101:16403-4
4. Sagnella G. 2000. Practical implications of current natriuretic peptide research. J. Renin Angiotensin Aldosterone Syst. 1:304-15
5. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, et al. 2001. Bone marrow cells regenerate infarcted myocardium. Nature 410:701-5
6. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, et al. 2003. Adult cardiac stem cells are multipotent and sup-port myocardial regeneration. Cell 114:763-76
7. Kapadia S, Dibbs Z, Kurrelmeyer K, Kalra D, Seta Y, et al. 1998. The role of cytokines in the failing human heart. Cardiol. Clin. 16:645-56
8. Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. 1997. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ. Res. 81:187-95
9. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. 1995. Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. 96:1042-52
10. Afanasyeva M, Georgakopoulos D, Belardi DF, Ramsundar AC, Barin JG, et al. 2004. Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: correlation with cardiac function. Am. J. Pathol. 164:807-15
11. Austyn J, Hankins D, Larsen C, Morris P, Rao A, Roake J. 1994. Isolation and characterization of dendritic cells from mouse heart and kidney. J. Immunol. 152:2401-10
12. Hart D, Fabre J. 1981. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J. Exp. Med. 154:347-61
13. Steiniger B, Klempnauer J, Wonigeit K. 1984. Phenotype and histological distribution of interstitial dendritic cells in the rat pancreas, liver, heart, and kidney. Transplantation 38:169-74
14. Spencer SC, Fabre JW. 1990. Characterization of the tissue macrophage and the interstitial dendritic cell as distinct leukocytes normally resident in the connective tissue of rat heart. J. Exp. Med. 171:1841-51
15. Medzhitov R, Janeway CA Jr. 2002. Decoding the patterns of self and nonself by the innate immune system. Science 296:298-300
16. Serrick C, Adoumie R, Giaid A, Shennib H. 1994. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 58:1158-62
17. Oz MC, Liao H, Naka Y, Seldomridge A, Becker DN, et al. 1995. Ischemia-induced interleukin-8 release after human heart transplantation. A potential role for endothelial cells. Circulation 92:11428-32
18. Gerlach J, Jorres A, Nohr R, Zeilinger K, Spatkowski G, Neuhaus P. 1999. Local liberation of cytokines during liver preservation. Transpl. Int. 12:261-65
19. Lemay S, Rabb H, Postler G, Singh AK. 2000. Prominent and sustained upregulation of gp130-signaling cytokines and the chemokine MIP-2 in murine renal ischemia-reperfusion injury. Transplantation 69:959-63
20. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. 1960. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch. Pathol. 70:68-78
21. Braunwald E, Maroko PR. 1974. The reduction of infarct size-an idea whose time (for testing) has come. Circulation 50:206-9
22. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, et al. 1971. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43:67-82
23. Nian M, Lee P, Khaper N, Liu P. 2004. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94:1543-53
24. Frangogiannis NG, Smith CW, Entman ML. 2002. The inflammatory response in myocardial infarction. Cardiovasc. Res. 53:31-47
25. Piper HM, Meuter K, Schafer C. 2003. Cellular mechanisms of ischemia-reperfusion injury. Ann. Thorac. Surg. 75: S644-48
26. Park JL, Lucchesi BR. 1999. Mechanisms of myocardial reperfusion injury. Ann. Thorac. Surg. 68:1905-12
27. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, et al. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146-51
28. Fitch JC, Rollins S, Matis L, Alford B, Aranki S, et al. 1999. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100:2499-506
29. Jordan JE, Zhao ZQ, Vinten-Johansen J. 1999. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 43:860-78
30. Simpson PJ, Todd RF III, Mickelson JK, Fantone JC, Gallagher KP, et al. 1990. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation 81:226-37
31. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. 1983. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67:1016-23
32. Patel BS, Jeroudi MO, O'Neill PG, Roberts R, Bolli R. 1990. Effect of human recombinant superoxide dismutase on canine myocardial infarction. Am. J. Physiol. 258:H369-80
33. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. 1984. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ. Res. 54:277-85
34. Bolli R, Jeroudi MO, Patel BS, Aruoma OI, Halliwell B, et al. 1989. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ. Res. 65:607-22
35. Mann DL. 2003. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu. Rev. Physiol. 65:81-101
36. Wilson EM, Diwan A, Spinale FG, Mann DE. 2004. Duality of innate stress responses in cardiac injury, repair, and remodeling. J. Mol. Cell Cardiol. 37:801-11
37. Wong GH, Goeddel DV. 1988. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242:941-44
38. Brown JM, White CW, Terada ES, Grosso MA, Shanley PF, et al. 1990. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA 87:5026-30
39. Eddy LJ, Goeddel DV, Wong GH. 1992. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem. Biophys. Res. Commun. 184:1056-59
40. Marber MS, Latchman DS, Walker JM, Yellon DM. 1993. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88:1264-72
41. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, et al. 1993. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ. Res. 72:1293-99
42. Hoshida S, Yamashita N, Otsu K, Hori M. 2002. Repeated physiologic stresses provide persistent cardioprotection against ischemia-reperfusion injury in rats. J. Am. Coll. Cardiol. 40:826-31
43. Yamashita N, Hoshida S, Otsu K, Taniguchi N, Kuzuya T, Hori M. 2000. The involvement of cytokines in the second window of ischaemic preconditioning. Br. J. Pharmacol. 131:415-22
44. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, et al. 2004. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc. Res. 64:61-71
45. Goldhaber JI, Kim KH, Natterson PD, Lawrence T, Yang P, Weiss JN. 1996. Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am. J. Physiol. 271: H1449-55
46. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. 1993. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J. Clin. Invest. 92:2303-12
47. Sun M, Opavsky MA, Stewart DJ, Rabinovitch M, Dawood F, et al. 2003. Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: regulation by cytokines. Circulation 107:1046-52
48. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, et al. 2001. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. USA 98:10344-49
49. Deten A, Holzl A, Leicht M, Barth W, Zimmer HG. 2001. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J. Mol. Cell Cardiol. 33:1191-207
50. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, et al. 2001. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J. Am. Coll. Cardiol. 38:1546-53
51. Roberts R, DeMello V, Sobel BE. 1976. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 53:1204-6
52. Brown JM, Grosso MA, Terada LS, Whitman GJR, Banerjee A, et al. 1989. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc. Natl. Acad. Sci. USA 86:2516-20
53. Chao W, Shen Y, Zhu X, Zhao H, Novikov M, et al. 2005. Lipopolysaccharide improves cardiomyocyte survival and function after serum deprivation. J. Biol. Chem. 280:21997-2005
54. Oyama J-I, Blais C Jr, Liu X, Pu M, Kobzik L, et al. 2004. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109:784-89
55. Nakamura H, Umemoto S, Naik G, Moe G, Takata S, et al. 2003. Induction of left ventricular remodeling and dysfunction in the recipient heart after donor heart myocardial infarction: new insights into the pathologic role of tumor necrosis factor-alpha from a novel heterotopic transplant-coronary ligation rat model. J. Am. Coll. Cardiol. 42:173-81
56. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. 1998. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98:149-56
57. Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, et al. 1999. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 99:1492-98
58. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. 1997. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95:1247-52
59. Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldman AM. 1997. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J. Card. Fail. 3:117-24
60. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, et al. 2001. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104:826-31
61. Bryant D, Becker L, Richardson J, Shelton J, Franco F, et al. 1998. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97:1375-81
62. Brown RD, Ambler SK, Mitchell MD, Long CS. 2005. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 45:657-87
63. Kajstura J, Rota M, Whang B, Cascapera S, Hosoda T, et al. 2005. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ. Res. 96:127-37
64. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, et al. 2001. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J. Clin. Invest. 107:1395-402
65. Bardales RH, Hailey LS, Xie SS, Schaefer RF, Hsu SM. 1996. In situ apoptosis assay for the detection of early acute myocardial infarction. Am. J. Pathol. 149:821-29
66. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. 2003. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ. Res. 92:139-50
67. Takemura G, Fujiwara H. 2004. Role of apoptosis in remodeling after myocardial infarction. Pharmacol. Ther. 104:1-16
68. Primeau AJ, Adhihetty PJ, Hood DA. 2002. Apoptosis in heart and skeletal muscle. Can. J. Appl. Physiol. 27:349-95
69. Wei GC, Sirois MG, Qu R, Liu P, Rouleau JL. 2002. Subacute and chronic effects of quinapril on cardiac cytokine expression, remodeling, and function after myocardial infarction in the rat. J. Cardiovasc. Pharmacol. 39:842-50
70. Sia YT, Parker TG, Tsoporis JN, Liu P, Adam A, Rouleau JL. 2002. Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. J. Cardiovasc. Pharmacol. 39:73-87
71. Gage JR, Fonarow G, Hamilton M, Widawski M, Martinez-Maza O, Vredevoe DL. 2004. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 11:173-80
72. Tatli E, Kurum T. 2005. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can. J. Cardiol. 21:344-48
73. Deten A, Volz HC, Holzl A, Briest W, Zimmer HG. 2003. Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats. Mol. Cell Biochem. 251:127-37
74. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, et al. 2004. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177:161-66
75. Holm T, Andreassen AK, Ueland T, Kjekshus J, Froland SS, et al. 2001. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am. J. Cardiol. 87:815-18, A9
76. Remme WJ. 2003. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. Cardiovasc. Drugs Ther. 17:349-60
77. Scalia R. 2005. Statins and the response to myocardial injury. Am. J. Cardiovasc. Drugs 5:163-70
78. Weitz-Schmidt G. 2002. Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23:482-86
79. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, et al. 2004. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594-602
80. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. 2003. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133-40
81. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, et al. 1996. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 93:841-42
82. Lower R. 1669. Tractatus de corde: item de motu & colore sanguinis, et chyli in eum transitu. Amsterdam: Elsevier. 232 pp.
83. Saphir O. 1941. Myocarditis: a general review, with an analysis of two hundred and forty cases. Arch. Pathol. 32:1000-51
84. Gore I, Saphir O. 1947. Myocarditis: a classification of 1402 cases. Am. Heart J. 34:827-30
85. Blankenhorn MA, Gall EA. 1956. Myocarditis and myocardosis; a clinicopathologic appraisal. Circulation 13:217-23
86. Feldman AM, McNamara D. 2000. Myocarditis. N. Engl. J. Med. 343:1388-98
87. Morris SA, Tanowitz HB, Wittner M, Bilezikian JP. 1990. Pathophysiological insights into the cardiomyopathy of Chagas' disease. Circulation 82:1900-9
88. Huber SA. 1997. Autoimmunity in myocarditis: relevance of animal models. Clin. Immunol. Immunopathol. 83:93-102
89. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. 2001. From infection to autoimmunity. J. Autoimmun. 16:175-86
90. Schwimmbeck PL, Badorff C, Rohn G, Schulze K, Schultheiss HP. 1996. The role of sensitized T-cells in myocarditis and dilated cardiomyopathy. Int. J. Cardiol. 54:117-25
91. Wolfgram LJ, Beisel KW, Herskowitz A, Rose NR. 1986. Variations in the susceptibility to coxsackievirus B3-induced myocarditis among different strains of mice. J. Immunol. 136:1846-52
92. Huber SA, Lodge PA. 1984. Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. Am. J. Pathol. 116:21-29
93. Fairweather D, Yusung S, Frisancho S, Barrett M, Gatewood S, et al. 2003. IL-12 receptor beta 1 and Toll-like receptor 4 increase IL-1 beta- and IL-18-associated myocarditis and coxsackievirus replication. J. Immunol. 170:4731-37
94. + Th1 cells. J. Virol. 76:10785-90
95. Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW. 1987. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to coxsackievirus B3-induced myocarditis. J. Immunol. 138:2488-92
96. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. 1987. Cardiac myosin induces myocarditis in genetically predisposed mice. J. Immunol. 139:3630-36
97. Fairweather D, Frisancho-Kiss S, Rose NR. 2005. Viruses as adjuvants for autoimmunity: evidence from coxsackievirus-induced myocarditis. Rev. Med. Virol. 15:17-27
98. Eriksson U, Penninger JM. 2005. Autoimmune heart failure: new understandings of pathogenesis. Int. J. Biochem. Cell Biol. 37:27-32
99. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. 1991. LPS promotes CB3-induced myocarditis in resistant B10.A mice. Cell. Immunol. 136:219-33
100. Eriksson U, Kurrer MO, Sonderegger I, Iezzi G, Tafuri A, et al. 2003. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J. Exp. Med. 197:323-31
101. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, et al. 2003. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat. Med. 9:1484-90
102. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. 1992. Interleukin 1 or tumor necrosis factor can promote coxsackie B3-induced myocarditis in resistant B10.A mice. J. Exp. Med. 175:1123-29
103. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, et al. 2001. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2:739-45
104. Eriksson U, Kurrer MO, Schmitz N, Marsch SC, Fontana A, et al. 2003. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 107:320-25
105. Grabie N, Delfs MW, Westrich JR, Love VA, Stavrakis G, et al. 2003. IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. J. Clin. Invest. 111:671-80
106. Land WG. 2005. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 79:505-14
107. Filatenkov AA, Jacovetty EL, Fischer UB, Curtsinger JM, Mescher MF, Ingulli E. 2005. CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance. J. Immunol. 174:6909-17
108. Saiki T, Ezaki T, Ogawa M, Matsuno K. 2001. Trafficking of host- and donor-derived dendritic cells in rat cardiac transplantation: allosensitization in the spleen and hepatic nodes. Transplantation 71:1806-15
109. Ratcliffe NR, Wegmann KW, Zhao RW, Hickey WF. 2000. Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells. J. Autoimmun. 15:369-79
110. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, et al. 2003. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. 9:1484-90
111. Eriksson U, Kurrer MO, Sonderegger I, Iezzi G, Tafuri A, et al. 2003. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J. Exp. Med. 197:323-31
112. Talmage DW, Dart G, Radovich J, Lafferty KJ. 1976. Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection. Science 191:385-88
113. Lechler RI, Batchelor JR. 1982. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J. Exp. Med. 155:31-41
114. Morelli AE, Thomson AW. 2003. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol. Rev. 196:125-46
115. Riquet M, Le Pimpec-Barthes F, Hidden G. 2001. Lymphatic drainage of the pericardium to the mediastinal lymph nodes. Surg. Radiol. Anat. 23:317-19
116. Palmer AS, Miller AJ, Greene R. 1998. The lymphatic drainage of the left ventricle in the Yucatan minipig. Lymphology 31:30-33
117. Miller AJ, DeBoer A, Pick R, Van Pelt L, Palmer AS, Huber MP. 1988. The lymphatic drainage of the pericardial space in the dog. Lymphology 21:227-33
118. Afanasyeva M, Georgakopoulos D, Rose NR. 2004. Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Autoimmun. Rev. 3:476-86
119. Guler ML, Ligons DL, Wang Y, Bianco M, Broman KW, Rose NR. 2005. Two autoimmune diabetes loci influencing T cell apoptosis control susceptibility to experimental autoimmune myocarditis. J. Immunol. 174:2167-73
120. Villasenor J, Benoist C, Mathis D. 2005. AIRE and APECED: molecular insights into an autoimmune disease. Immunol. Rev. 204:156-64
121. Gotter J, Brors B, Hergenhahn M, Kyewski B. 2004. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199:155-66
122. Smith S, Allen P. 1991. Myosin-induced acute myocarditis is a T cell-mediated disease. J. Immunol. 147:2141-47
123. Greenwald RJ, Freeman GJ, Sharpe AH. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-48
124. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-47
125. Oosterwegel MA, Mandelbrot DA, Boyd SD, Lorsbach RB, Jarrett DY, et al. 1999. The role of CTLA-4 in regulating Th2 differentiation. J. Immunol. 163:2634-39
126. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, et al. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-22
127. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, et al. 2003. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9:1477-83
128. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, et al. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33:2706-16
129. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027-34
130. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, et al. 2003. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur. J. Immunol. 33:3117-26
131. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, et al. 2004. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 101:10691-96
132. Cai G, Kami A, Oliveira EM, Weiner HL, Hafler DA, Freeman GJ. 2004. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell. Immunol. 230:89-98
133. Ozkaynak E, Wang L, Goodearl A, McDonald K, Qin S, et al. 2002. Programmed death-1 targeting can promote allograft survival. J. Immunol. 169:6546-53
134. Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, et al. 2005. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J. Immunol. 174:6648-56
135. Sospedra M, Martin R. 2004. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683-747
136. Raz I, Eldor R, Naparstek Y. 2005. Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol. 23:128-34
137. Hidalgo LG, Halloran PF. 2002. Role of IFN-gamma in allograft rejection. Crit. Rev. Immunol. 22:317-49
138. Berenson LS, Ota N, Murphy KM. 2004. Issues in T-helper 1 development-resolved and unresolved. Immunol. Rev. 202:157-74
139. Huber S. 2004. T cells in coxsackievirus-induced myocarditis. Viral Immunol. 17:152-64
140. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. 2001. From infection to autoimmunity. J. Autoimmun. 16:175-86
141. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, et al. 2005. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-γ and macrophage and neutrophil populations in the heart. J. Immunol. 174:261-69
142. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, et al. 2004. Interferon-γ protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-β1, interleukin-1β, and interleukin-4 in the heart. Am. J. Pathol. 165:1883-94
143. Smith S, Allen P. 1992. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ. Res. 70:856-63
144. Afanasyeva M, Wang Y, Kaya Z, Park S, Zilliox MJ, et al. 2001. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am. J. Pathol. 159:193-203
145. Afanasyeva M, Wang Y, Kaya Z, Stafford EA, Dohmen KM, et al. 2001. Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-γ-independent pathway. Circulation 104:3145-51
146. Eriksson U, Kurrer MO, Sebald W, Brombacher F, Kopf M. 2001. Dual role of the IL-12/IFN-γ axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-γ. J. Immunol. 167:5464-69
147. Eriksson U, Kurrer MO, Bingisser R, Eugster HP, Saremaslani P, et al. 2001. Lethal autoimmune myocarditis in interferon-γ receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation 103:18-21
148. Dalton DK, Haynes L, Chu C-Q, Swain SL, Wittmer S. 2000. Interferon γ eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J. Exp. Med. 192:117-22
149. Afanasyeva M, Georgakopoulos D, Belardi DF, Bedja D, Fairweather D, et al. 2005. Impaired up-regulation of CD25 on CD4+ T cells in IFN-γ knockout mice is associated with progression of myocarditis to heart failure. Proc. Natl. Acad. Sci. USA 102:180-85
150. Zettl UK, Mix E, Zielasek J, Stangel M, Hartung H-P, Gold R. 1997. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell. Immunol. 178:1-8
151. Dalton DK, Wittmer S. 2005. Nitric-oxide-dependent and independent mechanisms of protection from CNS inflammation during Th1-mediated autoimmunity: evidence from EAE in iNOS KO mice. J. Neuroimmunol. 160:110-21
152. Miura M, El-Sawy T, Fairchild RL. 2003. Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of Interferon-γ. Am. J. Pathol. 162:509-19
153. Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P. 1997. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J. Clin. Invest. 100:550-57
154. Halloran PF, Miller LW, Urmson J, Ramassar V, Zhu L-F, et al. 2001. IFN-γ alters the pathology of graft rejection: protection from early necrosis. J. Immunol. 166:7072-81
155. Grabie N, Hsieh DT, Buono C, Westrich JR, Allen JA, et al. 2003. Neutrophils sustain pathogenic CD8+ T cell responses in the heart. Am. J. Pathol. 163:2413-20
156. Zehntner SP, Brickman C, Bourbonniere L, Remington L, Caruso M, Owens T. 2005. Neutrophils that infiltrate the central nervous system regulate T cell responses. J. Immunol. 174:5124-31
157. Bettelli E, Kuchroo VK. 2005. IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together. J. Exp. Med. 201:169-71
158. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233-40
159. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, et al. 1987. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1:3-14
160. Ullal SR, Kluge TH, Kerth WJ, Gerbode F. 1972. Anatomical studies on lymph drainage of the heart in dogs. Ann. Surg. 175(3):305-10